Literature DB >> 11418607

Characterization of human mucin gene MUC4 promoter: importance of growth factors and proinflammatory cytokines for its regulation in pancreatic cancer cells.

M Perrais1, P Pigny, M P Ducourouble, D Petitprez, N Porchet, J P Aubert, I Van Seuningen.   

Abstract

The human mucin gene MUC4 encodes a large transmembrane mucin that is thought to play important roles in tumor cell biology and that is overexpressed in human pancreatic carcinomas. In this report, we describe the structure and functional activity of the 5'-flanking region, including 1.0 kilobase of the promoter. The long 5'-untranslated region (2.7 kilobases) is characterized by a high content of GC in its 3'-end. The first TATA box was located at -2672/-2668. Multiple transcription start sites and a high density of putative binding sites for Sp1 (GC and CACCC boxes), AP-1/-2/-4, cAMP-responsive element-binding protein, GATA, GR, and STAT transcription factors were found within the 5'-flanking region. Transcriptional activity of the promoter was assessed using pGL3-luciferase deletion mutants in two MUC4-expressing (CAPAN-1 and CAPAN-2) and one nonexpressing (PANC-1) pancreatic cancer cell line. Two highly active fragments (-219/-1 and -2781/-2572) that drive MUC4 transcription in CAPAN-1 and CAPAN-2 cells were identified. Gel retardation assays indicated that Sp1 and Sp3 bind to cognate cis-elements found in the 5'-flanking region and that Sp1 transactivates, whereas Sp3 inhibits the GC-rich region (-464/-1) in CAPAN-2 cells. Activation of protein kinase C with phorbol ester and treatment of cells with epidermal growth factor and transforming growth factor-alpha resulted in up-regulation of the promoter. Tumor necrosis factor-alpha and interferon (IFN)-gamma inflammatory cytokines had no or mild effect on MUC4 transcriptional activity when used alone. However, a very strong synergistic effect (10-12-fold activation) between IFN-gamma and tumor necrosis factor-alpha or IFN-gamma and transforming growth factor-alpha was obtained in CAPAN-2 cells. Altogether these results demonstrate that the 5'-flanking region of MUC4 contains epithelial cell-specific, positive, and negative regulatory cis-elements, that Sp1/Sp3 are important regulators of MUC4 basal expression, and that its regulation in pancreatic cancer cells involves complex interplay between several signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418607     DOI: 10.1074/jbc.M104204200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

Review 1.  Mucins and blastocyst attachment.

Authors:  Amantha Thathiah; Daniel D Carson
Journal:  Rev Endocr Metab Disord       Date:  2002-05       Impact factor: 6.514

Review 2.  The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 3.  Structure, evolution, and biology of the MUC4 mucin.

Authors:  Pallavi Chaturvedi; Ajay P Singh; Surinder K Batra
Journal:  FASEB J       Date:  2007-11-16       Impact factor: 5.191

Review 4.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

Authors:  Olga V Smirnova; Tatiana Yu Ostroukhova; Roman L Bogorad
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

5.  Transcriptional regulation of human mucin gene MUC4 in pancreatic cancer cells.

Authors:  Jingjing Zhang; Xiongfei Zhang; Yi Zhu; Zheng Chen; Zekuan Xu; Yi Miao
Journal:  Mol Biol Rep       Date:  2009-09-16       Impact factor: 2.316

Review 6.  Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer.

Authors:  Muzafar A Macha; Shiv Ram Krishn; Rahat Jahan; Kasturi Banerjee; Surinder K Batra; Maneesh Jain
Journal:  Cancer Treat Rev       Date:  2015-01-14       Impact factor: 12.111

7.  miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer.

Authors:  F Lahdaoui; Y Delpu; A Vincent; F Renaud; M Messager; B Duchêne; E Leteurtre; C Mariette; J Torrisani; N Jonckheere; I Van Seuningen
Journal:  Oncogene       Date:  2014-03-10       Impact factor: 9.867

8.  Transmembrane mucins as novel therapeutic targets.

Authors:  Pamela E Constantinou; Brian P Danysh; Neeraja Dharmaraj; Daniel D Carson
Journal:  Expert Rev Endocrinol Metab       Date:  2011-11

Review 9.  Muc4/MUC4 functions and regulation in cancer.

Authors:  Kermit L Carraway; George Theodoropoulos; Goldi A Kozloski; Coralie A Carothers Carraway
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

10.  Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression.

Authors:  N Jonckheere; V Fauquette; L Stechly; N Saint-Laurent; S Aubert; C Susini; G Huet; N Porchet; I Van Seuningen; P Pigny
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.